TCGA reported FGFR1 amplification and/or overexpression in 15% of ER+ breast cancers whereas in MONALEESA-2, we only detected FGFR1 amplification in ctDNA in 5% of plasma specimens. This evidence concerns the gene FGFR1 and breast carcinoma.